{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:33Z","timestamp":1789340373844,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"DOI":"10.1093\/jac\/dku088","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T00:18:17Z","timestamp":1396484297000},"page":"2187-2190","source":"Crossref","is-referenced-by-count":18,"title":["Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti"],"prefix":"10.1093","volume":"69","author":[{"given":"David W.","family":"Haas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Severe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Antoine","family":"Jean Juste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean William","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"key":"key\n\t\t\t\t20170425183900_DKU088C1","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170425183900_DKU088C2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170425183900_DKU088C3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425183900_DKU088C4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170425183900_DKU088C5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants","volume":"22","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170425183900_DKU088C6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiq043","article-title":"Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study","volume":"203","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170425183900_DKU088C7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0910370","article-title":"Early versus standard antiretroviral therapy for HIV-infected adults in Haiti","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170425183900_DKU088C8","author":"WHO"},{"key":"key\n\t\t\t\t20170425183900_DKU088C9","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/FPC.0b013e32835a5af2","article-title":"Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians","volume":"22","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170425183900_DKU088C10","article-title":"A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo controlled, non-inferiority trial"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T06:53:20Z","timestamp":1498114400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dku088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,2]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,4,2]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku088","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,2]]}}}